BPH is one of those conditions that affects a large population and has physical symptomology that makes sufferers very uncomfortable. These facts make it a great condition for DTC. Unfortunately, ...
RAPAFLO (Silodosin) 4mg, 8mg capsules by Watson The FDA has approved Rapaflo (silodosin, from Watson) for the treatment of benign prostatic hyperplasia (BPH). The FDA has approved Rapaflo (silodosin, ...
April 30, 2009 (Chicago, Illinois) — Results of 2 phase 3 studies reported here yesterday during the American Urological Association (AUA) 104th Annual Scientific Meeting show that silodosin (Rapaflo, ...
A website indicating that Actavis’s alpha-blocker Rapaflo capsules can improve sleep and daytime productivity prompted an untitled letter from the FDA’s Office of Prescription Drug Promotion. The drug ...
WASHINGTON — A branded drug made by Watson Pharmaceuticals reduced symptoms in men with prostate disease, according to results of a mid-stage clinical trial. Data from the phase-2 study of the drug ...
WASHINGTON, Oct. 13 (UPI) -- The U.S. Food and Drug Administration has approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia. "Benign prostatic ...
- RAPAFLO(R) demonstrated significant response in men with moderate to severe CP/CPPS - WASHINGTON, May 17, 2011 /PRNewswire/ -- New data presented today show that RAPAFLO(R) (silodosin) significantly ...
RAPAFLO (Silodosin) 4mg, 8mg capsules by Watson Watson has launched Rapaflo (silodosin capsules), a selective alpha-1 adrenergic receptor antagonist, for the treatment of the signs and symptoms of ...
NEW YORK, Oct 8 (Reuters) - U.S. health regulators have approved Watson Pharmaceuticals Inc's Rapaflo treatment for urination problems -- a condition known as benign prostatic hyperplasia (BPH), the ...
Camber has launched silodosin capsules. The product is the generic of Allergan’s Rapaflo capsules. It is used to treat the signs of an enlarged prostate. Camber’s silodosin capsules are available in 4 ...
PARSIPPANY, N.J., June 19, 2013 -- Actavis, Inc. (NYSE: ACT) and Kissei Pharmaceutical Co., LTD today confirmed that they have filed lawsuits against Sandoz Inc ...
PARSIPPANY, N.J., June 19, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) and Kissei Pharmaceutical Co., LTD today confirmed that they have filed lawsuits against Sandoz Inc., Hetero USA, Inc., Hetero ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results